Featured Event Transfiere 2023 Málaga España Del 15/02/2023 to 17/02/2023 Healthcare Agrifood Industrial biotechnology International AseBio will play a leading role in Transfiere 2023 with talks and a stand next month in Malaga to showcase the work of...
Featured Event Apply to the first edition of AseBio-Merck Award "Advanced Therapies Startup Competition" Madrid España Del 12/09/2022 to 05/10/2022 Healthcare Advanced therapies ¡Deadline extended! You can apply until October 5th
Featured Event Biotech Communications 101 Seminar - Consilium & AseBio Investor Day On-line Del 26/04/2022 15:00 to 26/04/2022 16:00 Healthcare Communication In the framework of the AseBio Investor Day 2022 that we are holding next Thursday 28th April, our partners have the...
Featured Event The Annual 2022 Two-Day IVD Conference Madrid España Del 24/03/2022 to 25/03/2022 Healthcare
What do the Catalan healthcare startups that raised the most funding in 2025 have in com... 10/07/2026 Healthcare Financing Communication The largest funding rounds of 2025 were concentrated in companies that combine an unmet need, solid evidence, and the... Partners - GENESIS Biomed
ORYZON announces U.S. patent grant for vafidemstat in borderline personality disorder (BP... 08/07/2026 Healthcare Rare diseases Innovative drugs Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD. Partners - Oryzon Genomics
Zoonotic diseases highlight the need to strengthen prevention and the One Health approach ... 06/07/2026 Healthcare Climate change Animal health Industrial biotechnology On World Zoonoses Day, we spoke with HIPRA, one of the European biotechnology companies most strongly committed to the... AseBio - HIPRA HUMAN HEALTH S.L.U.
Zoonotic diseases highlight the need to strengthen prevention and the One Health approach ... 06/07/2026 HIPRA HUMAN HEALTH S.L.U. Around 60% of human infectious diseases originate in animals. Climate change and globalization are reinforcing the need... AseBio - HIPRA HUMAN HEALTH S.L.U.
ORYZON raises €12 million and signs a financing agreement with COFIDES to strengthen its ... 03/07/2026 Healthcare Innovative drugs Financing Priced at €2.70 per share, representing a 14.15% discount on the five day VWAP and a 12.68% discount to the June 30... Partners - Oryzon Genomics
Immunological information: the new strategic infrastructure of personalised medicine 02/07/2026 Healthcare Personalized medicine Toni Vilaplana, CEO of Viva in Vitro Diagnostics. AseBio - VIVA IN VITRO
